Do analysts rate CALC or ARAV?

CalciMedica currently has a consensus price target of $10.00, suggesting a potential upside of 1,062.79%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than Aravive. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CalciMedica 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aravive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable earnings & valuation, CALC or ARAV?

CalciMedica is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio CalciMedica N/A N/A -$29.56M -$1.31 N/A Aravive N/A N/A N/A -$0.90 N/A

Is CALC or ARAV more profitable?

Aravive's return on equity of 0.00% beat CalciMedica's return on equity. Company Net Margins Return on Equity Return on Assets CalciMedica N/A -863.40% -144.33% Aravive N/A N/A N/A

Do analysts rate ARAV or AKAN?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aravive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Akanda 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has higher earnings and valuation, ARAV or AKAN?

Aravive has higher earnings, but lower revenue than Akanda. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aravive N/A N/A N/A -$0.90 N/A Akanda $840K 10.34 -$4.10M N/A N/A

Is ARAV or AKAN more profitable?

Company Net Margins Return on Equity Return on Assets Aravive N/A N/A N/A Akanda N/A N/A N/A

Do analysts prefer ARAV or APRE?

Aprea Therapeutics has a consensus price target of $4.07, indicating a potential upside of 419.37%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aprea Therapeutics is more favorable than Aravive. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aravive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Aprea Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has stronger valuation & earnings, ARAV or APRE?

Aprea Therapeutics is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Aravive N/A N/A N/A -$0.90 N/A Aprea Therapeutics N/A N/A -$12.60M -$1.54 N/A

Do analysts recommend BIVI or ARAV?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Aravive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has higher valuation & earnings, BIVI or ARAV?

BioVie is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio BioVie N/A N/A -$17.54M -$2.45 N/A Aravive N/A N/A N/A -$0.90 N/A

Is BIVI or ARAV more profitable?

Aravive's return on equity of 0.00% beat BioVie's return on equity. Company Net Margins Return on Equity Return on Assets BioVie N/A -101.15% -90.18% Aravive N/A N/A N/A

Do analysts prefer ARAV or BFRI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aravive 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Biofrontera 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Is ARAV or BFRI more profitable?

Aravive has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Aravive's return on equity of 0.00% beat Biofrontera's return on equity. Company Net Margins Return on Equity Return on Assets Aravive N/A N/A N/A Biofrontera -25.66% -515.34% -53.91%

Aravive (ARAV) Competitors

$0.04 0.00 (0.00%)

As of 06/3/2026

Compare

ARAV vs. CALC, AKAN, APRE, BIVI, and BFRI

Should you buy Aravive stock or one of its competitors? MarketBeat compares Aravive with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Aravive include CalciMedica (CALC), Akanda (AKAN), Aprea Therapeutics (APRE), BioVie (BIVI), and Biofrontera (BFRI). These companies are all part of the "pharmaceutical products" industry.

How does Aravive compare to CalciMedica?

CalciMedica (NASDAQ:CALC) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, valuation, dividends, profitability, earnings, institutional ownership and risk.

In the previous week, CalciMedica's average media sentiment score of 1.87 beat Aravive's score of 0.00 indicating that CalciMedica is being referred to more favorably in the media.

Company	Overall Sentiment
CalciMedica	Very Positive
Aravive	Neutral

Aravive's return on equity of 0.00% beat CalciMedica's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CalciMedica	N/A	-863.40%	-144.33%
Aravive	N/A	N/A	N/A

CalciMedica is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CalciMedica	N/A	N/A	-$29.56M	-$1.31	N/A
Aravive	N/A	N/A	N/A	-$0.90	N/A

CalciMedica currently has a consensus price target of $10.00, suggesting a potential upside of 1,062.79%. Given CalciMedica's stronger consensus rating and higher possible upside, analysts plainly believe CalciMedica is more favorable than Aravive.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CalciMedica	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aravive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

35.8% of Aravive shares are held by institutional investors. 41.5% of CalciMedica shares are held by company insiders. Comparatively, 60.4% of Aravive shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Summary

Aravive beats CalciMedica on 6 of the 10 factors compared between the two stocks.

How does Aravive compare to Akanda?

Aravive (NASDAQ:ARAV) and Akanda (NASDAQ:AKAN) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, dividends, analyst recommendations, institutional ownership and earnings.

In the previous week, Akanda had 1 more articles in the media than Aravive. MarketBeat recorded 1 mentions for Akanda and 0 mentions for Aravive. Akanda's average media sentiment score of 0.94 beat Aravive's score of 0.00 indicating that Akanda is being referred to more favorably in the news media.

Company	Overall Sentiment
Aravive	Neutral
Akanda	Positive

Aravive has higher earnings, but lower revenue than Akanda.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	N/A	N/A	N/A	-$0.90	N/A
Akanda	$840K	10.34	-$4.10M	N/A	N/A

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
Akanda	N/A	N/A	N/A

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aravive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Akanda	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

35.8% of Aravive shares are held by institutional investors. Comparatively, 1.0% of Akanda shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Comparatively, 20.4% of Akanda shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Akanda beats Aravive on 4 of the 6 factors compared between the two stocks.

How does Aravive compare to Aprea Therapeutics?

Aravive (NASDAQ:ARAV) and Aprea Therapeutics (NASDAQ:APRE) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, institutional ownership, dividends, risk, profitability, analyst recommendations, valuation and media sentiment.

Aravive has a net margin of 0.00% compared to Aprea Therapeutics' net margin of -4,405.59%. Aravive's return on equity of 0.00% beat Aprea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
Aprea Therapeutics	-4,405.59%	-61.03%	-50.24%

Aprea Therapeutics is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	N/A	N/A	N/A	-$0.90	N/A
Aprea Therapeutics	N/A	N/A	-$12.60M	-$1.54	N/A

Aprea Therapeutics has a consensus price target of $4.07, indicating a potential upside of 419.37%. Given Aprea Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Aprea Therapeutics is more favorable than Aravive.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aravive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Aprea Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

35.8% of Aravive shares are owned by institutional investors. Comparatively, 34.2% of Aprea Therapeutics shares are owned by institutional investors. 60.4% of Aravive shares are owned by insiders. Comparatively, 13.6% of Aprea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Aprea Therapeutics had 3 more articles in the media than Aravive. MarketBeat recorded 3 mentions for Aprea Therapeutics and 0 mentions for Aravive. Aprea Therapeutics' average media sentiment score of 0.84 beat Aravive's score of 0.00 indicating that Aprea Therapeutics is being referred to more favorably in the news media.

Company	Overall Sentiment
Aravive	Neutral
Aprea Therapeutics	Positive

Summary

Aravive beats Aprea Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Aravive compare to BioVie?

BioVie (NASDAQ:BIVI) and Aravive (NASDAQ:ARAV) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, valuation, institutional ownership, dividends, risk, media sentiment, analyst recommendations and earnings.

In the previous week, BioVie had 3 more articles in the media than Aravive. MarketBeat recorded 3 mentions for BioVie and 0 mentions for Aravive. BioVie's average media sentiment score of 0.76 beat Aravive's score of 0.00 indicating that BioVie is being referred to more favorably in the media.

Company	Overall Sentiment
BioVie	Positive
Aravive	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Aravive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Aravive's return on equity of 0.00% beat BioVie's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-101.15%	-90.18%
Aravive	N/A	N/A	N/A

4.6% of BioVie shares are held by institutional investors. Comparatively, 35.8% of Aravive shares are held by institutional investors. 0.9% of BioVie shares are held by insiders. Comparatively, 60.4% of Aravive shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

BioVie is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$17.54M	-$2.45	N/A
Aravive	N/A	N/A	N/A	-$0.90	N/A

Summary

Aravive beats BioVie on 6 of the 9 factors compared between the two stocks.

How does Aravive compare to Biofrontera?

Aravive (NASDAQ:ARAV) and Biofrontera (NASDAQ:BFRI) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, earnings, media sentiment, valuation, profitability, dividends, risk and analyst recommendations.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aravive	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Biofrontera	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

35.8% of Aravive shares are held by institutional investors. Comparatively, 10.1% of Biofrontera shares are held by institutional investors. 60.4% of Aravive shares are held by company insiders. Comparatively, 4.8% of Biofrontera shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Aravive has higher earnings, but lower revenue than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than Aravive, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aravive	N/A	N/A	N/A	-$0.90	N/A
Biofrontera	$41.71M	0.31	-$10.54M	-$0.97	N/A

In the previous week, Biofrontera had 2 more articles in the media than Aravive. MarketBeat recorded 2 mentions for Biofrontera and 0 mentions for Aravive. Biofrontera's average media sentiment score of 0.91 beat Aravive's score of 0.00 indicating that Biofrontera is being referred to more favorably in the news media.

Company	Overall Sentiment
Aravive	Neutral
Biofrontera	Positive

Aravive has a net margin of 0.00% compared to Biofrontera's net margin of -25.66%. Aravive's return on equity of 0.00% beat Biofrontera's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Aravive	N/A	N/A	N/A
Biofrontera	-25.66%	-515.34%	-53.91%

Summary

Aravive beats Biofrontera on 7 of the 12 factors compared between the two stocks.

Get Aravive News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ARAV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ARAV vs. The Competition

Export

Metric	Aravive	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	N/A	$3.28B	$6.32B	$12.38B
Dividend Yield	N/A	2.36%	2.69%	5.31%
P/E Ratio	-0.04	18.46	23.73	24.35
Price / Sales	N/A	187.54	498.78	95.26
Price / Cash	N/A	111.03	41.39	55.53
Price / Book	N/A	6.77	9.96	6.72
Net Income	N/A	$24.09M	$3.56B	$337.03M
7 Day Performance	N/A	-3.20%	-1.04%	-0.16%
1 Month Performance	N/A	0.36%	2.18%	3.74%
1 Year Performance	N/A	49.44%	28.93%	34.34%

Aravive Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ARAV Aravive	N/A	$0.04 flat	N/A	N/A	$0.00	N/A	N/A	20	High Trading Volume
CALC CalciMedica	2.501 of 5 stars	$0.74 -2.0%	$10.00 +1,243.0%	-49.9%	$11.76M	N/A	N/A	30	Positive News Gap Down
AKAN Akanda	0.6884 of 5 stars	$21.67 -9.2%	N/A	-83.8%	$11.49M	$840K	N/A	110	Gap Down
APRE Aprea Therapeutics	3.6117 of 5 stars	$0.91 +0.5%	$4.07 +344.6%	-59.6%	$11.33M	N/A	N/A	7	News Coverage
BIVI BioVie	0.4287 of 5 stars	$1.48 +2.8%	N/A	-84.2%	$11.16M	N/A	N/A	10

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ARAV) was last updated on 6/5/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Aravive (ARAV) Competitors